TABLE 3.
Cytopathic effect (CPE) reduction assay results of the six predicted compounds toward the wild-type strain A/Minfang/151/2000 (H3N2)
| Compound | Pretreatment | Simultaneous treatment | Posttreatment | Pre-incubation treatment | ||||
|---|---|---|---|---|---|---|---|---|
| IC50 | SI | IC50 | SI | IC50 | SI | IC50 | SI | |
| Acacetin | 7.7 ± 1.6 | >12.99 | 13.62 ± 2.72 | >7.34 | 9.21 ± 0.87 | >10.86 | 9.41 ± 0.54 | >10.63 |
| Eupatorin | 69.31 ± 1.97 | >1.44 | 40.75 ± 1.15 | >2.45 | 73.85 ± 1.34 | >1.35 | 92.58 ± 0.33 | >1.08 |
| Dinatin | ND | ND | ND | ND | ND | ND | ND | ND |
| Linarin | 81.85 ± 2.76 | >1.22 | 41.96 ± 1.29 | >2.38 | 86.35 ± 9.88 | >1.16 | 77.71 ± 3.08 | >1.29 |
| Tryptanthrin | 46.35 ± 2.05 | >2.16 | 40.32 ± 1.81 | >2.48 | 91.84 ± 13.1 | >1.09 | 71.72 ± 0.44 | >1.39 |
| Indirubin | 77.23 ± 6 | >1.29 | ND | ND | 84.93 ± 5.09 | >1.18 | 55.45 ± 2.03 | >1.8 |
| Zanamivira | 0.78 ± 0.29 | >128.21 | 0.38 ± 0.05 | >263.16 | 0.98 ± 0.14 | >102.04 | 1.02 ± 0.28 | >98.04 |
The experiments were conducted with four different time points for drug administration (pretreatment, simultaneous treatment, posttreatment, and pre-incubation treatment) and repeated three times. Detailed description of the drug administration mode can be found in Materials and Methods. Data are expressed as the mean ± SD (n = 3).
IC 50 , 50% effective concentration (in micrograms per milliliter); ND, not detected (IC50 > 100 µg/ml); SI, selection index (TC50/IC50)
aPositive control drug